OSII participated in the large partnering conference BIO, in early June. Follow-up includes pitching collaboration ideas to many companies interested in academic collaborations, including J&J/Janssen, Boerhinger Ingelheim, Daiichi Sankyo, AbbVie, and Pfizer. Please visit the Industry Interests page to see if your research aligns with theirs. If so, please contact me to organize information for a pitch to the company.
UPCOMING AREA EVENTS/OPPORTUNITIES
The University of Texas at Austin's Biomedical Department of Biomedical Engineering is soliciting medical device design projects for their senior design capstone course. Several UTHealth faculty have participated in previous cohorts and were able to assist the teams in developing prototypes for their idea. IP generated is assigned to UTHealth.
Deadline for submitting is September 30. Contact Melissa Thompson (email@example.com) for more information.
2018 Texas Advanced Computing Center Symposium for Texas Researchers
September 20-21, 2018
UPCOMING APPLICATION DEADLINES/EVENTS:
September 30: FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use Disorder
October 21: Deadline for next TMCx Digital Health Applications Cohort
|What, Why, Where, When and How to hold your first First-In-Human trial
SEP 25 | Webinar
This clinical trial workshop will bring together experts in the field from Johnson & Johnson, CROs and agencies to discuss advantages, challenges and experiences in running trials around the globe.
SAVE THE DATE: OCT 3 | Houston, TX
JLABS @ TMC and AT&T Foundry are partnering together to show you how digital health is changing healthcare.
|The Path to a Small Molecule IND
OCT 11 | Webinar
Start-ups are expected to demonstrate a clear blueprint for IND approval, and we want you to be ready.
SELECTED UPDATES FROM 2017:
OSII serves as a megaphone to amplify access and response to industry-funded research opportunities, including the Sanofi iAward program. Thus far, three faculty members have been awarded iAwards for their projects: Dr. Joseph McCormick, School of Public Health Brownsville; Dr. Xiaodong Cheng, Texas Therapeutics Institute and Department of Integrative Biology and Pharmacology; Dr. Priyatansh Gurha, Center for Cardiovascular Genetics at the Institute for Molecular Medicine. In each case, OSII assisted in the application process as well as the post-award phase, in coordination with Sponsored Projects Administration, Technology Management, and the Committee for Protection of Human Subjects (as applicable). For more, see the Funding Opportunities page.
Dr. Gargi Mukherji and Dr. Ralph Cooley, both School of Dentistry faculty members, envisioned a new dental product that would prevent objects used during procedures from falling down the esophagus or trachea when accidentally dropped. OSII assisted Drs. Mukherji and Cooley to conceive and implement a strategy to seek a commercial partner, which lead to a collaborative relationship with Zirc Dental Products. Together with Zirc, the idea was formalized for production, which led to a new patent application, and the new product is currently in clinical testing at the School of Dentistry. Upon successful testing, Zirc will manufacture and commercialize the product as part of their dental portfolio with royalties leading back to Dr. Mukherji, Dr. Cooley and UTHealth.
Dr. John Hagan, Assistant Professor in Neurosurgery, discovered a novel target for cancer treatment with unique potential for small molecule-based development. He proposed a project to GlaxoSmithKline’s Discovery Partnerships with Academia (DPAc), and with OSII assistance, Dr. Hagan became one of the select few to participate in the program as well as receive some additional funding for research in his lab to support the project. The project is on-going and has led to further interactions between the DPAc team and other UTHealth faculty, as well as a strong relationship with the DPAc group enabling mentoring opportunities with GSBS students and further relationships within GSK.
Kiss Industries, LLC reached out to UTHealth with an opportunity to test the efficacy of their new product: new type of gum with the potential to prevent plaque formation and gingivitis called Confadent. After some research, OSII connected Kiss with Dr. Nikola Angelov and Dr. Flavia Lakschevitz at the School of Dentistry, who have extensive experience in periodontal disease and treatment, to design and conduct the trial. Because Kiss is a start-up company with limited funding for a trial but the research presented a unique scientific opportunity, OSII, together with Technology Management, established a new funding paradigm to bridge the funding gap. Ultimately, this opportunity provides mutual benefits to both parties, and may lead to additional collaborative research projects between Kiss and UTHealth.
UTHealth recognizes the increasingly significant role of industrial relationships in enabling academic research “to advance the quality of human life by enhancing the diagnosis, treatment, and prevention of disease and injury…”
The primary purpose of OSII is to:
- Foster stronger strategic relationships between UTHealth faculty and industry
- Manage and coordinate corporate collaborations and seed funding opportunities for the commercial advancement of UTHealth technologies
For more information, see the menu for further information "For Researchers" or "For Industry". See below for current funding opportunities and upcoming events.
To received emails to learn about new opportunities and events, email Melissa Thompson.